Insiders · Profile

LYONS GARY A

Director at Travere Therapeutics · Director at NEUROCRINE BIOSCIENCES. Filing since 15 Sep 2014. CIK 0001123343

Company
Date
Role
Action
Shares
Amount
Of holding
18 Aug 2026
Director
Sold on a plan
5,000
$316.86K
7.5%
17 Aug 2026
Director
Sold on a plan
5,000
$315.99K
7.5%
14 Apr 2026
Director
Sold on a plan
8,000
$328.56K
12.2%
3 Dec 2025
Director
Sold on a plan
15,000
$2.29M
11.1%
4 Oct 2024
Director
Sold on a plan
40,000
$589.10K
44.0%
13 Aug 2024
Director
Sold on a plan
11,570
$1.74M
8.9%
16 Jul 2024
Director
Sold on a plan
930
$139.53K
0.8%
14 May 2024
Director
Sold on a plan
12,500
$1.70M
9.7%
22 Dec 2023
Director
Sold on a plan
10,000
$1.30M
4.9%
1 Dec 2023
Director
Sold on a plan
5,000
$583.84K
2.4%
12 Sep 2023
Director
Sold on a plan
5,000
$575.12K
2.4%
1 Sep 2023
Director
Sold on a plan
5,000
$550.32K
2.4%
31 Oct 2022
Director
Sold, plan not stated
15,000
$1.72M
6.9%
4 Oct 2022
Director
Sold, plan not stated
5,000
$552.71K
2.4%
25 Apr 2022
Director
Sold, plan not stated
15,000
$1.39M
6.7%
7 Oct 2021
Director
Sold, plan not stated
5,000
$525.29K
2.3%
10 Jun 2021
Director
Sold, plan not stated
10,000
$1.00M
4.5%
26 Jan 2021
Director
Sold, plan not stated
400
$48.00K
0.2%
25 Jan 2021
Director
Sold, plan not stated
1,600
$192.05K
0.7%
8 Nov 2019
Director
Sold, plan not stated
5,000
$550.00K
2.2%
1 Nov 2019
Director
Sold, plan not stated
5,000
$501.10K
2.1%
30 Jul 2019
Director
Sold, plan not stated
10,000
$920.69K
4.1%
2 Nov 2018
Director
Sold, plan not stated
15,000
$1.72M
5.8%
13 Jun 2018
Director
Sold, plan not stated
15,000
$1.49M
5.4%
15 Feb 2018
Director
Sold, plan not stated
5,000
$423.34K
1.9%
5 Feb 2018
Director
Sold, plan not stated
5,000
$415.38K
1.8%
1 Dec 2017
Director
Sold, plan not stated
10,000
$729.18K
3.5%
18 Sep 2015
Director
Sold, plan not stated
15,000
$823.30K
5.6%
24 Mar 2015
Director
Sold, plan not stated
30,000
$1.25M
10.1%
15 Sep 2014
Director
Sold, plan not stated
20,000
$313.20K
6.6%
30 decisions on file.